WO2009130198A3 - Hyperglycosylated human coagulation factor ix - Google Patents

Hyperglycosylated human coagulation factor ix Download PDF

Info

Publication number
WO2009130198A3
WO2009130198A3 PCT/EP2009/054707 EP2009054707W WO2009130198A3 WO 2009130198 A3 WO2009130198 A3 WO 2009130198A3 EP 2009054707 W EP2009054707 W EP 2009054707W WO 2009130198 A3 WO2009130198 A3 WO 2009130198A3
Authority
WO
WIPO (PCT)
Prior art keywords
coagulation factor
human coagulation
polypeptides
hyperglycosylated human
hyperglycosylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/054707
Other languages
French (fr)
Other versions
WO2009130198A2 (en
Inventor
Gert Bolt
Claus Kristensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to US12/937,331 priority Critical patent/US20110137011A1/en
Priority to CN2009801244941A priority patent/CN102105582A/en
Priority to JP2011505482A priority patent/JP5665733B2/en
Priority to EP09734022A priority patent/EP2268807A2/en
Publication of WO2009130198A2 publication Critical patent/WO2009130198A2/en
Publication of WO2009130198A3 publication Critical patent/WO2009130198A3/en
Anticipated expiration legal-status Critical
Priority to US13/723,576 priority patent/US8871714B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention relates to hyperglycosylated human coagulation factor IX polypeptides, to processes for preparing said polypeptides, to pharmaceutical compositions comprising said polypeptides and to the use of the compounds for the treatment of diseases alleviated by human coagulation factor IX, in particular, but not exclusively hemophilia.
PCT/EP2009/054707 2008-04-21 2009-04-21 Hyperglycosylated human coagulation factor ix Ceased WO2009130198A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US12/937,331 US20110137011A1 (en) 2008-04-21 2009-04-21 Hyperglycosylated human coagulation factor ix
CN2009801244941A CN102105582A (en) 2008-04-21 2009-04-21 Hyperglycosylated human coagulation factor IX
JP2011505482A JP5665733B2 (en) 2008-04-21 2009-04-21 Highly glycosylated human coagulation factor IX
EP09734022A EP2268807A2 (en) 2008-04-21 2009-04-21 Hyperglycosylated human coagulation factor ix
US13/723,576 US8871714B2 (en) 2008-04-21 2012-12-21 Hyperglycosylated human coagulation factor IX

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08103629.5 2008-04-21
EP08103629 2008-04-21

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/937,331 A-371-Of-International US20110137011A1 (en) 2008-04-21 2009-04-21 Hyperglycosylated human coagulation factor ix
US13/723,576 Continuation US8871714B2 (en) 2008-04-21 2012-12-21 Hyperglycosylated human coagulation factor IX

Publications (2)

Publication Number Publication Date
WO2009130198A2 WO2009130198A2 (en) 2009-10-29
WO2009130198A3 true WO2009130198A3 (en) 2010-05-06

Family

ID=41217185

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/054707 Ceased WO2009130198A2 (en) 2008-04-21 2009-04-21 Hyperglycosylated human coagulation factor ix

Country Status (5)

Country Link
US (2) US20110137011A1 (en)
EP (3) EP2268807A2 (en)
JP (2) JP5665733B2 (en)
CN (1) CN102105582A (en)
WO (1) WO2009130198A2 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2423307A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
AU2008311973B2 (en) * 2007-10-15 2013-10-03 Cangene Corporation Human Factor IX variants with an extended half life
ES2985035T3 (en) 2008-09-15 2024-11-04 Uniqure Biopharma B V Factor IX polypeptide mutant, its uses and its production process
MX375112B (en) 2010-07-09 2025-03-06 Biogen Hemophilia Inc FACTOR IX POLYPEPTIDES AND METHODS OF USING THEM.
WO2012045769A1 (en) 2010-10-05 2012-04-12 Novo Nordisk Health Care Ag Process for protein production
TWI595004B (en) 2010-11-03 2017-08-11 介控生化科技公司 Modified ninth factor multi-peptide and use thereof
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
EA028914B1 (en) 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Assays to monitor bleeding disorders
UY34317A (en) 2011-09-12 2013-02-28 Genzyme Corp T cell antireceptor antibody (alpha) / ß
WO2014018777A2 (en) 2012-07-25 2014-01-30 Biogen Idec Ma Inc. Blood factor monitoring assay and uses thereof
KR102049900B1 (en) * 2012-07-25 2019-11-28 카탈리스트 바이오사이언시즈, 인코포레이티드 Modified factor X polypeptides and uses thereof
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
FI3366705T3 (en) * 2012-09-12 2023-07-28 Genzyme Corp Fc containing polypeptides with altered glycosylation and reduced effector function
WO2014052490A1 (en) 2012-09-25 2014-04-03 Biogen Idec Ma Inc. Methods of using fix polypeptides
AU2013331000B2 (en) 2012-10-18 2018-04-19 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
RS61387B2 (en) 2013-02-15 2024-06-28 Bioverativ Therapeutics Inc Optimized factor viii gene
US9580511B2 (en) 2013-03-11 2017-02-28 Genzyme Corporation Site-specific antibody-drug conjugation through glycoengineering
SG11201507524TA (en) * 2013-03-14 2015-10-29 Amgen Inc Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods
SG11201601182QA (en) * 2013-09-30 2016-04-28 Crucell Holland Bv Method for the clarification of high density crude cell culture harvest
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
WO2015095809A1 (en) 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
HUE061339T2 (en) 2014-03-19 2023-06-28 Genzyme Corp Site-specific glycoengineering of targeting moieties
EA202092926A3 (en) 2014-03-24 2021-10-29 Биовератив Терапьютикс Инк. LYOPHILIZED COMPOSITIONS CONTAINING FACTOR IX
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
WO2017011336A1 (en) 2015-07-10 2017-01-19 E.&J. Gallo Winery System and method for dispensing a beverage
UA126016C2 (en) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Factor ix fusion proteins and methods of making and using same
KR20180118659A (en) 2016-02-01 2018-10-31 바이오버라티브 테라퓨틱스 인크. Optimized Factor VIII Factor
KR20190090827A (en) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. How Chimeric Coagulation Factors Can Be Used to Treat Hemophilic Arthrosis
BR112019015569A2 (en) 2017-01-31 2020-03-17 Bioverativ Therapeutics Inc. FACTOR IX FUSION PROTEINS AND METHODS FOR THEIR PRODUCTION AND USE
MX2020001593A (en) 2017-08-09 2020-07-13 Bioverativ Therapeutics Inc NUCLEIC ACID MOLECULES AND USES THEREOF.
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
KR20200057051A (en) 2017-09-27 2020-05-25 시질론 테라퓨틱스, 인크. Methods, compositions and implantable elements comprising active cells
CN112203646A (en) 2018-04-04 2021-01-08 西吉隆医疗股份有限公司 Implantable particles and related methods
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
KR102914074B1 (en) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. Treatment of hemophilia A
JP7602454B2 (en) 2018-08-09 2024-12-18 バイオベラティブ セラピューティクス インコーポレイテッド Nucleic Acid Molecules and Their Use for Non-Viral Gene Therapy - Patent application
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
UY38389A (en) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc IMPLANTABLE DEVICES FOR CELLULAR THERAPY AND RELATED METHODS
JP7575401B2 (en) 2019-04-03 2024-10-29 ジェンザイム・コーポレーション Anti-alpha beta TCR binding polypeptides with reduced fragmentation - Patents.com
WO2020215010A1 (en) 2019-04-17 2020-10-22 Codiak Biosciences, Inc. Compositions of exosomes and aav
JP7803014B2 (en) 2019-09-30 2026-01-21 バイオベラティブ セラピューティクス インコーポレイテッド Lentiviral vector formulations
EP4061942A4 (en) 2019-11-22 2023-12-20 Sigilon Therapeutics, Inc. Monoclonal cell lines expressing an exogenous substance and uses thereof
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
JP2023537565A (en) 2020-06-24 2023-09-04 バイオベラティブ セラピューティクス インコーポレイテッド Methods for removing free factor VIII from preparations of lentiviral vectors modified to express proteins
CN120659872A (en) 2022-10-11 2025-09-16 西吉隆医疗股份有限公司 Engineered cells and implantable elements for treating diseases
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020004483A1 (en) * 2000-01-10 2002-01-10 Nissen Torben Lauesgaard G-CSF conjugates
WO2005024006A2 (en) * 2003-09-09 2005-03-17 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
US20050095668A1 (en) * 2000-10-18 2005-05-05 Maxygen Aps Protein C or activated protein C-like molecules
WO2007111496A1 (en) * 2006-03-28 2007-10-04 Universiteit Utrecht Holding B.V. Improved carbohydrate recognition domains
WO2009051717A2 (en) * 2007-10-15 2009-04-23 The University Of North Carolina At Chapel Hill Human factor ix variants with an extended half life

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984000560A1 (en) * 1982-08-04 1984-02-16 Nat Res Dev Molecular cloning of the gene for human anti-haemophilic factor ix
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
IL110669A (en) 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
HUP0203751A3 (en) * 2000-01-10 2005-01-28 Maxygen Holdings Ltd Redwood C G-csf conjugates
WO2001058935A2 (en) * 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
US20030036181A1 (en) * 2000-06-30 2003-02-20 Okkels Jens Sigurd Peptide extended glycosylated polypeptides
AU1038802A (en) * 2000-10-18 2002-04-29 Maxygen Aps Protein c or activated protein c-like molecules
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
CA2522345A1 (en) * 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
RU2396347C2 (en) 2004-08-17 2010-08-10 Ксл Бехринг Гмбх Modified vitamin k dependent polypeptides
US20080255026A1 (en) * 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP2423307A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020004483A1 (en) * 2000-01-10 2002-01-10 Nissen Torben Lauesgaard G-CSF conjugates
US20050095668A1 (en) * 2000-10-18 2005-05-05 Maxygen Aps Protein C or activated protein C-like molecules
WO2005024006A2 (en) * 2003-09-09 2005-03-17 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
WO2007111496A1 (en) * 2006-03-28 2007-10-04 Universiteit Utrecht Holding B.V. Improved carbohydrate recognition domains
WO2009051717A2 (en) * 2007-10-15 2009-04-23 The University Of North Carolina At Chapel Hill Human factor ix variants with an extended half life

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MIMURO J ET AL: "Specific detection of human coagulation factor IX in cynomolgus macaques", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, BLACKWELL PUBLISHING, OXFORD, GB, vol. 2, no. 2, 1 February 2004 (2004-02-01), pages 275 - 280, XP009125189, ISSN: 1538-7933, [retrieved on 20040107] *

Also Published As

Publication number Publication date
JP5665733B2 (en) 2015-02-04
WO2009130198A2 (en) 2009-10-29
EP2444491A3 (en) 2012-08-08
CN102105582A (en) 2011-06-22
JP2015038075A (en) 2015-02-26
EP2268807A2 (en) 2011-01-05
EP2444491A2 (en) 2012-04-25
EP2444491B1 (en) 2016-11-16
US8871714B2 (en) 2014-10-28
US20130095555A1 (en) 2013-04-18
EP2811017A2 (en) 2014-12-10
JP2011517954A (en) 2011-06-23
US20110137011A1 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
EP2444491A3 (en) Hyperglycosylated human coagulation factor IX
WO2011060049A3 (en) Spiro-oxindole mdm2 antagonists
WO2012065022A3 (en) Spiro-oxindole mdm2 antagonists
MY150285A (en) 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use
TN2011000466A1 (en) Substituted 2-acetamido -5-aryl-1, 2, 4- triazolones and use thereof
WO2011084808A3 (en) Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
IL209121A (en) Indazolyl derivatives, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment of inflammatory diseases
WO2009065406A3 (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2012078593A3 (en) Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
WO2012058393A3 (en) Dkk1 antibodies and methods of use
WO2011044506A3 (en) Sulphone compounds for use in the treatment of obesity
IL216399A0 (en) Pharmaceutical composition for the treatment of heart diseases
WO2010130832A3 (en) Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
IL220682A0 (en) 1h-quinazoline-2,4-diones, processes for their manufacture, and use thereof in the preparation of medicaments for treating conditions mediated by the ampa-receptor
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
MX369417B (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases.
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
WO2009062576A8 (en) Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
WO2011069037A3 (en) Stabilization and storage of biological pharmaceutical compositions
MY150931A (en) Substituted oxazolidinones and their use
WO2011058245A8 (en) Novel mannopyranoside derivatives with anticancer activity
MX2012000954A (en) Pharmaceutical compositions.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980124494.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09734022

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009734022

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011505482

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12937331

Country of ref document: US